ARVN - Arvinas, Inc.

Insider Sale by Cacace Angela M (Chief Scientific Officer)

1 Month
After Trade
Before Trade

Loading data...

Trade Summary

4 days ago, Cacace Angela M, serving as Chief Scientific Officer at Arvinas, Inc. (ARVN), sold 3,609 shares at $12.16 per share, for a total transaction value of $43,885.00. Following this transaction, Cacace Angela M now holds 147,623 shares of ARVN.

This sale represents a 2.00% decrease in Cacace Angela M's stake in the company. This is considered a medium-conviction trade.

The trade was executed on Monday, February 23, 2026 and publicly disclosed via SEC Form 4 filing on Wednesday, February 25, 2026, 2 days after the trade was made.

Arvinas, Inc. operates in the HEALTHCARE sector, specifically within the BIOTECHNOLOGY industry. Insider selling activity in this sector can provide valuable signals about industry trends and company-specific developments.

Cacace Angela M

Chief Scientific Officer

Angela M. Cacace, Ph.D. is the Chief Scientific Officer (CSO) at Arvinas, Inc. (ARVN), appointed to the role on June 17, 2024, after serving as Senior Vice President of Neuroscience and Platform Biology since joining the company on September 4, 2018.[[1]](https://www.arvinas.com/leadership/angela-m-cacace-ph-d/)[[2]](https://fintool.com/app/research/companies/ARVN/people/angela-cacace) With over three decades of experience in drug discovery across neuroscience and oncology, she has led the evolution of Arvinas' PROTAC Discovery Engine, incorporating new E3 ligases and enabling blood-brain barrier penetration for neurologic targets, including advancing the first CNS-penetrant PROTAC, ARV-102, into clinical development.[[1]](https://www.arvinas.com/leadership/angela-m-cacace-ph-d/)[[3]](https://convention.bio.org/speakers/angela-cacace) Dr. Cacace previously served as Vice President of Biology at Fulcrum Therapeutics (2016–2018), where she built the biology platform and delivered development candidates for rare diseases; as Director of Neuroscience and Genetically Defined Diseases at Bristol-Myers Squibb (over 20 years total), spearheading alternative modalities and co-inventing development candidates; and as Senior Principal Scientist in Cancer Biology at Pfizer, discovering a novel anti-angiogenic antibody candidate.[[1]](https://www.arvinas.com/leadership/angela-m-cacace-ph-d/)[[2]](https://fintool.com/app/research/companies/ARVN/people/angela-cacace)[[3]](https://convention.bio.org/speakers/angela-cacace) She holds a B.S. in Biology from Fairfield University, a Ph.D. in Pharmacology from Columbia University, and completed postdoctoral research in Oncology at Bristol-Myers Squibb and the National Cancer Institute.[[1]](https://www.arvinas.com/leadership/angela-m-cacace-ph-d/)[[2]](https://fintool.com/app/research/companies/ARVN/people/angela-cacace) Recently, as a corporate insider, she sold 4,592 shares of ARVN on February 13, 2026, to cover tax withholding obligations related to vesting restricted stock units.[[4]](https://www.moomoo.com/news/post/65764102/insider-sale-chief-scientific-officer-of-arvn-sells-4592-shares)[[5]](https://www.investing.com/news/insider-trading-news/arvinas-cso-cacace-sells-54598-in-shares-93CH-4512385)

View full insider profile →

Trade Price

$12.16

Quantity

3,609

Total Value

$43,885.00

Shares Owned

147,623

Trade Date

Monday, February 23, 2026

4 days ago

SEC Filing Date

Wednesday, February 25, 2026

Filed 2 days after trade

HEALTHCAREBIOTECHNOLOGY

About Arvinas, Inc.

Company Overview

No company information available
View news mentioning ARVN

💬 Want Deeper Insight?

Use our AI assistant to ask questions about this trade, the insider, or the company.

Chat with AI

Share this trade

https://insidersignal.ai/trade/4296751

🚀 Track Insider Trades in Real-Time

Create a free account to access our full database of insider trades, AI-powered analysis, price alerts, and discover what corporate executives are buying and selling.

✓ Free forever plan available  •  ✓ No credit card required  •  ✓ Cancel anytime